US Stock MarketDetailed Quotes
NGNE Neurogene
- 20.300
- +4.710+30.21%
Close Nov 22 16:00 ET
- 20.700
- +0.400+1.97%
Post 20:01 ET
301.55MMarket Cap-7168P/E (TTM)
20.930High15.480Low1.06MVolume15.480Open15.590Pre Close20.14MTurnover16.04%Turnover RatioLossP/E (Static)14.85MShares74.49052wk High2.19P/B134.49MFloat Cap12.49052wk Low--Dividend TTM6.63MShs Float1115.000Historical High--Div YieldTTM34.96%Amplitude7.500Historical Low18.943Avg Price1Lot Size
About Neurogene Company
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
Company Profile
SymbolNGNE
Company NameNeurogene
Listing DateMar 7, 2014
Founded2007
CEOMr. Richard K. Matros
MarketNASDAQ
Employees91
Fiscal Year Ends12-31
Address535 West 24th Street,5th floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10011
Phone1-877-237-5020
Websitehttp://www.neurogene.com
Company Executives
- Name
- Position
- Salary
- Dr. Rachel McMinn, PhD
- Executive Chairman of the Board and Chief Executive Officer
- 1.08M
- Christine Mikail Cvijic, J.D.
- President and Chief Financial Officer
- 1.13M
- Dr. Stuart Cobb, PhD
- Chief Scientific Officer
- 784.32K
- Dr. Julie Jordan, M.D.
- Chief Medical Officer
- --
- Donna Cochener
- Senior Vice President and General Counsel
- --
- Dr. Cory Freedland, PhD
- Independent Director
- --
- Rohan Palekar
- Independent Director
- 71.62K
- Robert Keith Woods
- Independent Director
- --
- Dr. Sarah B. Noonberg, M.D.,PhD
- Independent Director
- 62.12K
- Dr. Robert A. Baffi,PhD
- Independent Director
- 64.08K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
